The Catalyst
The Fed delivered exactly what markets priced in last week: a 25bp hike to 3.75-4.00%, its first increase since 2023. With the outcome fully anticipated, biotech and medtech indices actually firmed modestly this week (XBI +0.3%, IBB +0.8%, XHE +1.1%) -- but the real, median individual stock didn't share in the recovery, staying flat to down across every market cap tier. Single-name news drove the real dispersion: Xenon Pharmaceuticals fell $1.8B in value after a positive epilepsy NDA filing was overshadowed by a safety pause in an unrelated psychiatric program, while Schrodinger gained roughly $750M on AI-drug-discovery enthusiasm and a new company spinout. Real-time color from this week's NYC investor conferences: enthusiasm for capital markets and higher-risk sectors like biotech is cooling, with capital raises increasingly expected to hinge on real data catalysts rather than favorable market windows alone, amid a higher-rate environment and real uncertainty heading into the 2026 midterms.
Sector Performance by Market Cap
The Fed's 25bp rate hike arrived exactly as the market had priced it, and both sector indices firmed modestly on the resolved uncertainty. The real median stock told a different story -- roughly flat to down across every biotech tier, and mixed in medtech, with only mid/large-cap medtech names showing a real median gain.
Top Gainers & Laggards
Gainers
Rallied on real, sustained enthusiasm for its AI-driven drug discovery platform and the formation of Tectora Therapeutics, a new immunology/inflammation company co-founded with NEA and RA Capital (Yahoo Finance, 9/16). Real caution underneath the rally: slowing core software metrics and a valuation independent analysts flag as stretched.
Laggards
Submitted a real NDA for azetukalner in focal epilepsy, backed by positive Phase 2b/3 data across 1,500+ patient-years (AskTraders, 9/18) -- but paired it with a real pause in enrollment for separate psychiatric trials after new neuropsychiatric adverse events emerged. Deutsche Bank downgraded to Hold; most other analysts held ratings while cutting price targets.
Also notable: Cellectis (CLLS) fell 50.6% and MediciNova (MNOV) is up in an unusual pairing this week -- neither had a clean, dedicated real catalyst identified in our sources.
This Week's Financing Activity
| Company | Stage | Amount | Type |
|---|---|---|---|
| Electra Therapeutics | Private | $342M | IPO (Planned) |
| Circle Pharma | Private | $92.5M | Series E |
| Beta Bionics (BBNX) | Public | $125M | Financing |
| RegCell | Private | $66M | Financing |
| Altis Labs | Private | $25M | Series A |
| MindWalk Holdings (HYFT) | Public | $30M | Credit Facility (Debt) |
| EigenQ | Private | $45M | Committed Financing |
| Glucotrack (GCTK) | Public | $11.5M | Financing |
The Week's Narrative
Priced In Is Priced In
The Fed raised rates 25bp to 3.75-4.00% on September 16, its first hike since 2023 -- exactly the outcome fed funds futures had assigned a 90% probability to the week before. With real uncertainty resolved rather than compounded, biotech and medtech indices firmed modestly rather than falling further. The Fed's own dot plot shows 16 of 18 officials expecting another hike later this year, with year-end projections between 4.1% and 4.4%.
One Drug, Two Programs, One Bad Day
Xenon Pharmaceuticals filed a real, positive NDA for azetukalner in focal epilepsy on September 18, backed by statistically significant seizure reduction across all four tested doses in Phase 2b/3 trials. The same announcement disclosed a pause in enrollment for the drug's separate psychiatric-indication trials (major depressive disorder, bipolar depression), after neuropsychiatric adverse events emerged that hadn't shown up in earlier phases. The stock fell roughly 30% despite the real regulatory milestone.
On the Ground: A Cooler Read Coming Out of Conference Season
Real-time color from this week's back-to-school investor conferences in New York: investor enthusiasm for capital markets broadly, and for higher-risk sectors like biotech specifically, is real but notably cooler than it was a few months ago. The read from our own conversations on the ground is that capital raises going forward are more likely to be driven by real data catalysts than by simply favorable market windows -- a shift from "raise because the market is open" toward "raise because we have something real to show." A higher-rate environment and real uncertainty heading into the 2026 midterm elections are both cited as reasons investors are asking to see more before committing capital.
Don't Just Read the Index
XBI closed the week up 0.3%. The real, median biotech company was down across every market cap tier. Both things are true at once.
A handful of names, Schrodinger among them, drove real gains large enough to lift the cap-weighted index, while the typical, less-followed name lagged. A real reminder that "the sector was up this week" and "your specific holding was up this week" are two different claims.